XACDURO®, The First and Only Antibiotic Developed to Ta

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...

Related Keywords

United States , Margaret Koziel , Tragiannidisa Acinetobacter , Pavel Raifeld , Innoviva Inc , Securities Exchange , National Review Drug Discovery , Drug Administration , Jolla Pharmaceutical Company , Entasis Therapeutics Inc , World Health Organization , Exchange Commission , Nasdaq , International Journal Of Infectious Disease , Centers For Disease , Glaxo Group Limited , Yuk National Prevalence , Innoviva Specialty Therapeutics Inc , Urgent Public Health Threat In United States , Innoviva Specialty Therapeutics , Chief Executive Officer , Infectious Disease , Chief Medical Officer , Disease Control , Full Prescribing Information , Specialty Therapeutics , Specialty Therapeutic , Long Acting Beta , Collaboration Agreement , Private Securities Litigation Reform Act , Securities Exchange Act , Financial Condition , Annual Report , Quarterly Reports , Single Pathogen Antibacterial , National Review Drug , International Journal , Safety Of Sulbactam , Durlobactam Versus Colistin , Non Inferiority Clinical Trial , Published May , Loading Dose Colistin , Carbapenem Resistant Acinetobacter , Critically Ill , Risk Factors , Clinical Presentation , Antibiotic Resistance , Resistant Acinetobacter , Health Organization , Markets ,